HCW Biologics (NASDAQ:HCWB) Director Scott Garrett Buys 7,736 Shares

HCW Biologics Inc. (NASDAQ:HCWB) Director Scott Garrett purchased 7,736 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were bought at an average price of $2.58 per share, with a total value of $19,958.88. Following the acquisition, the director directly owned 41,644 shares of the company’s stock, valued at $107,441.52. This represents a 22.81% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

HCW Biologics Stock Performance

NASDAQ HCWB opened at $3.20 on Friday. The company has a market capitalization of $5.12 million, a PE ratio of -0.06 and a beta of 2.29. HCW Biologics Inc. has a 52-week low of $1.50 and a 52-week high of $44.10. The company has a 50-day simple moving average of $6.50 and a 200 day simple moving average of $5.20.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of ($2.64) by $3.01. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%. The company had revenue of $6.54 million for the quarter, compared to analysts’ expectations of $6.54 million.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HCWB. Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research report on Friday, July 17th. Wall Street Zen raised HCW Biologics to a “hold” rating in a report on Saturday, May 23rd. Finally, Maxim Group lifted their target price on HCW Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, May 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $30.00.

Institutional Trading of HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC purchased a new stake in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics as of its most recent SEC filing. Institutional investors own 2.96% of the company’s stock.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.